LE WE PMID CA
GSK33719GSK3

4F2 LAT

Amyotrophic lateral sclerosis

APC (Adenomatous polyposis coli)

ASCT2

ASIC1

Atherosclerosis (BASKET)

Bipolar disorder

Cell Death (Lipoapoptosis)

Cell volume

CFTR ABCC7

Cholesterol

CLCN2 ClC2

CNS (Development)

CNS (Microglia)

Differentiation inducing factors DIF from Dictyostelium discoideum

EAAT1

EAAT2

EAAT3

EAAT4

EAAT5

ERS UFR (Diseases)

ERS UFR (Induced Mediators)

ERS UFR (Toxikologie)

Fatty acids (Free)

Fatty acids (saturated)

GADD153 CHOP

Glucocorticoids

GluR6

GLUT1

GSK3

Interleukin24 MDA7

Ion channel (BASKET)

Ion channel (Sodium ENaC)

Ischemia reperfusion

JNK

KCNQ1

KCNQ2

KCNQ3

KCNQ4

KCNQ5

Kir1 1 ROMK

Kv1 1

Kv1 2

Kv1 3

Kv1 4

Kv1 5

Lipotoxicity

Lithium

Lysophosphatidylcholine

Mineralocorticoids

mTORC2

NaDC

NaPiIIb

NCC

Nedd4 2

Neuroprotective agents

Neurotrophin

NHE3

NKCC2

Nrf2

P53

Palmitate

PepT2

Phosphomannomutase 2 PMM2

Placenta (Pathology)

Protein kinase B Akt

PTEN MMAC1 TEP1

PUMA

Receptor (Interleukin20)

Regeneration of tissues and other biologic structures

SCN5A

SGK1

SLC2A4 GLUT4

SLC5A1 SGLT1

SMIT

SN1

STAT3

Tau

TRPV5

TRPV6

Valproic acid

VSOAC

Wnt beta Catenin TCF

2004  
1
Glycogen synthase kinase 3: a drug target for CNS therapies.
[15189333] J Neurochem 89(6): 1313-7 (2004)
2009  
2
Glycogen synthase kinase 3: more than a namesake.
[19366350] Br J Pharmacol 156(6): 885-98 (2009)
2009  
3
Regulation of protein stability by GSK3 mediated phosphorylation.
[19923896] Cell Cycle 8(24): 4032-9 (2009)
2009  
4
GSK-3beta, a therapeutic target for cardiomyocyte protection.
[19506320] Circ J 73(7): 1184-92 (2009)
2002  
5
Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development.
[12039794] Circ Res 90(10): 1055-63 (2002)
2009  
6
Role of glycogen synthase kinase-3beta in cardioprotection.
[19498210] Circ Res 104(11): 1240-52 (2009)
2003  
7
GSK-3: tricks of the trade for a multi-tasking kinase.
[12615961] J Cell Sci 116(Pt 7): 1175-86 (2003)
2009  
8
Unique and overlapping functions of GSK-3 isoforms in cell differentiation and proliferation and cardiovascular development.
[19064989] J Biol Chem 284(15): 9643-7 (2009)
2010  
9
Significance of SGK1 in the regulation of neuronal function.
[20530112] J Physiol 588(Pt 18): 3349-54 (2010)
2009  
10
Drug development targeting the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: inhibitors of the Wnt/beta-catenin signaling pathway as novel anticancer drugs.
[19179804] J Pharmacol Sci 109(2): 179-83 (2009)
2009  
11
Drug development targeting the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: role of GSK-3beta in myocardial protection against ischemia/reperfusion injury.
[19179805] J Pharmacol Sci 109(2): 162-7 (2009)
2009  
12
Drug development targeting the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: targeting the Wnt pathway and transplantation therapy as strategies for retinal repair.
[19179807] J Pharmacol Sci 109(2): 168-73 (2009)
2009  
13
Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3beta, beta-catenin, and neurotrophin cascades.
[19423950] J Pharmacol Sci 110(1): 14-28 (2009)
2010  
14
GSK3beta: role in therapeutic landscape and development of modulators.
[20331603] Br J Pharmacol 160(1): 1-19 (2010)
2008  
15
Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis.
[18204489] Br J Pharmacol 153 Suppl 1(-): S137-53 (2008)
2010  
16
GSK3: a multifaceted kinase in Wnt signaling.
[19884009] Trends Biochem Sci 35(3): 161-8 (2010)
2005  
17
mda-7/IL24 kills pancreatic cancer cells by inhibition of the Wnt/PI3K signaling pathways: identification of IL-20 receptor-mediated bystander activity against pancreatic cancer.
[15851011] Mol Ther 11(5): 724-33 (2005)
2009  
18
Valproate attenuates accelerated atherosclerosis in hyperglycemic apoE-deficient mice: evidence in support of a role for endoplasmic reticulum stress and glycogen synthase kinase-3 in lesion development and hepatic steatosis.
[19095952] Am J Pathol 174(1): 330-42 (2009)
2008  
19
Evidence of placental translation inhibition and endoplasmic reticulum stress in the etiology of human intrauterine growth restriction.
[18583310] Am J Pathol 173(2): 451-62 (2008)
2012  
20
Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis.
[21995961] Am J Physiol Gastrointest Liver Physiol 302(1): G77-84 (2012)
2004  
21
Control of tumor suppressor p53 function by endoplasmic reticulum stress.
[15107622] Cell Cycle 3(5): 567-70 (2004)
2005  
22
Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs.
[15827567] Neuropsychopharmacology 30(7): 1223-37 (2005)
2007  
23
GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder.
[17499358] Neurosci Biobehav Rev 31(6): 920-31 (2007)
2009  
24
Wnt signaling as a therapeutic target for bone diseases.
[19335070] Expert Opin Ther Targets 13(4): 485-96 (2009)
2011  
25
Brief review of the role of glycogen synthase kinase-3β in amyotrophic lateral sclerosis.
[21603026] Neurol Res Int 2011(-): 205761 (2011)
2011  
26
GSK-3: Functional Insights from Cell Biology and Animal Models.
[22110425] Front Mol Neurosci 4(-): 40 (2011)
2011  
27
GSK-3 Mouse Models to Study Neuronal Apoptosis and Neurodegeneration.
[22110426] Front Mol Neurosci 4(-): 45 (2011)
2011  
28
Role of GSK3 Signaling in Neuronal Morphogenesis.
[22131966] Front Mol Neurosci 4(-): 48 (2011)
2011  
29
Glycogen synthase kinase-3 in the etiology and treatment of mood disorders.
[21886606] Front Mol Neurosci 4(-): 16 (2011)
2011  
30
Modulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies.
[22007157] Front Mol Neurosci 4(-): 24 (2011)
2007  
31
Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics.
[16944320] Neurochem Res 32(4-5): 577-95 (2007)
2007  
32
In search of the Holy Grail for the treatment of neurodegenerative disorders: has a simple cation been overlooked?
[17572175] Biol Psychiatry 62(1): 4-6 (2007)
2011  
33
Targeting Glycogen Synthase Kinase-3β for Therapeutic Benefit against Oxidative Stress in Alzheimer's Disease: Involvement of the Nrf2-ARE Pathway.
[21629716] Int J Alzheimers Dis 2011(-): 985085 (2011)
2011  
34
Glycogen synthase kinase-3β: a mediator of inflammation in Alzheimer's disease?
[21629736] Int J Alzheimers Dis 2011(-): 129753 (2011)
2011  
35
Functional implications of glycogen synthase kinase-3-mediated tau phosphorylation.
[21776376] Int J Alzheimers Dis 2011(-): 352805 (2011)
2010  
36
Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3).
[19836308] Trends Immunol 31(1): 24-31 (2010)
2008  
37
The GSK-3/beta-catenin-signalling axis in smooth muscle and its relationship with remodelling.
[18612673] Naunyn Schmiedebergs Arch Pharmacol 378(2): 185-91 (2008)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.



  • GSK3

  • The BDOM Bibliographic Dictionary of Medicine is a curated collection of free medical articles tagged to concepts.
    Contents until 2011 are reviews from PubMed, contents flagged 'PMC' are regular articles from PubMed Central.
    Search BDOM
    Nephrology Collection
    Radiology Locator

    PubMedCentral monthly collection of free medical articles by major subject

    The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia